Å. Borg

Å. Borg, H. Jernström, H. Olsson, 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease.

Å. Borg, N. Loman, O. Johannsson, 1998, Cancer research.

Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility

J. Benítez, Å. Borg, R. Schmutzler, 2017, Genetics in Medicine.

Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study

A. Børresen-Dale, Å. Borg, L. Bernstein, 2010, Breast Cancer Research and Treatment.

Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report.

C. Begg, J. Olsen, Å. Borg, 2013, European journal of cancer.

Flow cytometry DNA analysis and prediction of loco-regional recurrences after mastectomy in breast cancer.

M. Fernö, Å. Borg, S. Rydén, 1992, Acta oncologica.

Multiple metastases from cutaneous malignant melanoma patients may display heterogeneous genomic and epigenomic patterns

M. Ringnér, Å. Borg, H. Olsson, 2010, Melanoma research.

Prediction of Lymph Node Metastasis in Breast Cancer by Gene Expression and Clinicopathological Models: Development and Validation within a Population-Based Cohort

L. Saal, Å. Borg, N. Loman, 2019, Clinical Cancer Research.

A Naturally Occurring Allele of BRCA1 Coding for a Temperature-Sensitive Mutant Protein

Å. Borg, J. Vallon-Christersson, B. Billack, 2002, Cancer biology & therapy.

Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters.

A. Børresen-Dale, C. Larsson, Å. Borg, 1998, Cancer research.

L. Saal, Å. Borg, S. Gruvberger-Saal, 2015, Oncotarget.

Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing.

Å. Borg, N. Loman, H. Olsson, 2005, European journal of cancer.

Population-Based Study of the Risk of Second Primary Contralateral Breast Cancer Associated With Carrying a Mutation in BRCA 1 or BRCA 2

C. Begg, Å. Borg, J. Boice, 2010 .

p53 mutation and cyclin D1 amplification correlate with cisplatin sensitivity in xenografted human squamous cell carcinomas from head and neck

Å. Borg, B. Baldetorp, J. Wennerberg, 2006, Acta oncologica.

The mutational landscape of the SCAN‐B real‐world primary breast cancer transcriptome

L. Saal, Å. Borg, N. Loman, 2020, EMBO molecular medicine.

HER2-encoded mir-4728 forms a receptor-independent circuit with miR-21-5p through the non-canonical poly(A) polymerase PAPD5

R. Søkilde, Å. Borg, M. D. de Hoon, 2016, Scientific Reports.

CD 44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers

M. Ringnér, L. Saal, M. Fernö, 2011 .

Remarkably Distinct Gene Expression Patterns Estrogen Receptor Status in Breast Cancer Is Associated with Updated

S. Gruvberger, M. Ringnér, S. Panavally, 2001 .

Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism.

Å. Borg, R. Dziadziuszko, J. Jassem, 2006, Lung cancer.

CYP 17 genotype is associated with short menstrual cycles , early oral contraceptive use and BRCA mutation status in young healthy women

Å. Borg, H. Jernström, M. Henningson, 2007 .

Comparison of cisplatin sensitivity and the 18F fluoro-2-deoxy 2 glucose uptake with proliferation parameters and gene expression in squamous cell carcinoma cell lines of the head and neck

Å. Borg, P. Bendahl, F. Mertens, 2009, Journal of experimental & clinical cancer research : CR.

Haplotype analysis and age estimation of the 113insR CDKN2A founder mutation in Swedish melanoma families

Å. Borg, H. Olsson, C. Ingvar, 2001, Genes, chromosomes & cancer.

High Frequency of Multiple Melanomas and Breast and Pancreas Carcinomas in CDKN2A Mutation-Positive Melanoma Families

Å. Borg, O. Johannsson, H. Olsson, 2000 .

Novel germline p16 mutation in familial malignant melanoma in southern Sweden.

Å. Borg, O. Johannsson, H. Olsson, 1996, Cancer research.

Exploring the link between MORF4L1 and risk of breast cancer

S. Seal, N. Rahman, F. Couch, 2011, Breast Cancer Research.

Differences in IGFBP-3 regulation between young healthy women from BRCAX families and those belonging to BRCA1/2 families

Å. Borg, H. Jernström, H. Olsson, 2006, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

BRCA1 andBRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age

J. Olsen, Å. Borg, J. Bergthórsson, 2001, Journal of medical genetics.

A screening for BRCA1 mutations in breast and breast-ovarian cancer families from the Stockholm region.

Å. Borg, A. Lindblom, K. Sandelin, 1997, Cancer research.

Allelic loss at chromosome 13q12-q13 is associated with poor prognosis in familial and sporadic breast cancer.

Å. Borg, O. Johannsson, H. Olsson, 1996, British Journal of Cancer.

Correlation between p53 mutation and cyclin D1 amplification in had and neck squamous cell carcinoma.

Å. Borg, M. Dictor, J. Wennerberg, 1997, Oral oncology.

CHEK2*1100delC is not an important high-risk gene in families with hereditary prostate cancer in southern Sweden

Å. Borg, A. Giwercman, O. Bratt, 2006, Scandinavian journal of urology and nephrology.

Breast cancer survival in Nordic BRCA2 mutation carriers—unconventional association with oestrogen receptor status

E. Hovig, Å. Borg, N. Loman, 2020, British Journal of Cancer.

Molecular Characterization of Melanoma Cases in Denmark Suspected of Genetic Predisposition

N. Hayward, Å. Borg, K. Klein, 2015, PloS one.

Reproductive factors in hereditary breast cancer

Å. Borg, N. Loman, H. Olsson, 1999, Breast Cancer Research and Treatment.

No Significant Difference in Age at Menarche, Menstrual Cycle Length, Age at First Full-Term Pregnancy, and Nulliparity Among BRCA1 Mutation Carriers Compared with Their Unaffected Relatives

Å. Borg, O. Johannsson, H. Jernström, 2001 .

Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland

Jaana M. Hartikainen, J. Kere, E. Gillanders, 2000, European Journal of Human Genetics.

Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D

Julie O. Culver, F. Couch, S. Gruber, 2020, Journal of the National Cancer Institute.

The BRCA1 syndrome and other inherited breast or breast-ovarian cancers in a Norwegian prospective series.

K. Heimdal, P. Møller, E. Hovig, 2001, European journal of cancer.

Early oral contraceptive use and premenopausal breast cancer--a review of studies performed in southern Sweden.

M. Fernö, J. Ranstam, Å. Borg, 1991, Cancer Detection and Prevention.

Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.

Hoda Anton-Culver, Colin B Begg, Marinela Capanu, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Exploring the link between MORF4L1 and risk of breast cancer

S. Seal, N. Rahman, F. Couch, 2011 .

Array-CGH identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid carcinoma.

C. Larsson, Amy Y. M. Au, Å. Borg, 2008, Endocrine-related cancer.

Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).

W. Chung, F. Couch, B. Bonanni, 2020, JAMA oncology.

Identification of a novel splice‐site mutation of the BRCA1 gene in two breast cancer families: Screening reveals low frequency in Icelandic breast cancer patients

A. Jonasdottir, Å. Borg, J. Bergthórsson, 1998, Human mutation.

Written pretest information and germline BRCA1/2 pathogenic variant testing in unselected breast cancer patients: predictors of testing uptake

Å. Borg, N. Loman, M. Nilsson, 2018, Genetics in Medicine.

A biological marker, strongly associated with early oral contraceptive use, for the selection of a high risk group for premenopausal breast cancer

M. Fernö, J. Ranstam, Å. Borg, 1986, Medical oncology and tumor pharmacotherapy.

Guidelines for Follow-Up of Women at High Risk for Inherited Breast Cancer: Consensus Statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer

J. Chang-Claude, K. Heimdal, P. Møller, 2002, Disease markers.

Transcription of human endogenous retroviral sequences related to mouse mammary tumor virus in human breast and placenta: similar pattern in most malignant and nonmalignant breast tissues.

Å. Borg, H. Olsson, J. Blomberg, 1997, AIDS research and human retroviruses.

Recurrence-free survival in breast cancer improved by adjuvant tamoxifen -especially for progesterone receptor positive tumors with a high proliferation

M. Fernö, Å. Borg, H. Olsson, 2004, Breast Cancer Research and Treatment.

Recurrent 10q22-q23 deletions: a genomic disorder on 10q associated with cognitive and behavioral abnormalities.

S. Selleck, Å. Borg, D. Avramopoulos, 2007, American journal of human genetics.

Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer

M. Daly, D. Altshuler, F. Couch, 2010, PLoS Genetics.

Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden.

M. King, Å. Borg, O. Johannsson, 1996, American journal of human genetics.

p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma.

Å. Borg, M. Dictor, J. Wennerberg, 1998, British Journal of Cancer.

CDKN2A genetic testing in melanoma-prone families in Sweden in the years 2015–2020: implications for novel national recommendations

K. Nielsen, J. Lapins, Å. Borg, 2021, Acta oncologica.

Chromosomal translocations involving 11q13 contribute to cyclin D1 overexpression in squamous cell carcinoma of the head and neck.

Å. Borg, J. Isola, F. Mertens, 2002, International journal of oncology.

Screening for Copy Number Alterations and Loss of Heterozygosity in Chronic Lymphocytic Leukemia - A Comparative Study of Four Differently Designed, High Resolution Microarray Platforms.

Å. Borg, A. Syvänen, J. Staaf, 2007 .

Higher occurrence of childhood cancer in families with germline mutations in BRCA2, MMR and CDKN2A genes

Å. Borg, M. Nilbert, H. Olsson, 2008, Familial Cancer.

The retinoblastoma gene in breast cancer: allele loss is not correlated with loss of gene protein expression.

Å. Borg, H. Olsson, Hampus Olsson, 1992, Cancer research.

An exon 5 deletion variant of the estrogen receptor frequently coexpressed with wild-type estrogen receptor in human breast cancer.

Å. Borg, S. Fuqua, Q. X. Zhang, 1993, Cancer research.

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer

Wei Lu, Wei Zheng, Mads Thomassen, 2013, Nature Genetics.

A novel p53 germline alteration identified in a late onset breast cancer kindred.

Å. Borg, O. Johannsson, H. Olsson, 1996, Oncogene.

Frequent somatic loss of BRCA1 in breast tumours from BRCA2 germ-line mutation carriers and vice versa

Å. Borg, O. Johannsson, J. Isola, 2001, British Journal of Cancer.

Do BRCA1 mutations affect the ability to breast feed? Significantly shorter length of breast feeding among BRCA1 mutation carriers compared with their unaffected relatives.

Å. Borg, O. Johannsson, H. Jernström, 1998 .

Chromosome aberrations in prophylactic mastectomies from women belonging to breast cancer families

Å. Borg, H. Olsson, F. Mitelman, 1996 .

Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma.

Thomas M. Keane, K. Brown, J. Trent, 2015, Journal of the National Cancer Institute.

Melanoma and nonmelanoma skin cancer in patients with multiple tumours—evidence for new syndromes in a population‐based study

K. Nielsen, Å. Borg, H. Olsson, 2004, The British journal of dermatology.

Loss of heterozygosity at 11q23.1 and survival in breast cancer: Results of a large European study

M. Beckmann, A. Børresen-Dale, D. Birnbaum, 1999, Genes, chromosomes & cancer.

Microsatellite instability is rare in rectal carcinomas and signifies hereditary cancer.

Å. Borg, M. Nilbert, M. Planck, 1999, European journal of cancer.

Loss of heterozygosity at 7q31 in breast cancer: results from an International Collaborative Study Group. The Breast Cancer Somatic Genetics Consortium.

Å. Borg, J. Eyfjörd, P. Devilee, 1997, Genes, chromosomes & cancer.

Tiling-resolution array-CGH reveals the pattern of DNA copy number alterations in acute lymphoblastic leukemia with 21q amplification: the result of telomere dysfunction and breakage/fusion/breakage cycles?

Å. Borg, A. Nordgren, E. Blennow, 2007, Leukemia.

hMLH1, hMSH2 and hMSH6 mutations in hereditary non‐polyposis colorectal cancer families from Southern Sweden

Å. Borg, H. Olsson, P. Mangell, 1999, International journal of cancer.

Swedish CDKN2A mutation carriers do not present the atypical mole syndrome phenotype

K. Nielsen, Å. Borg, H. Olsson, 2010, Melanoma research.

Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women.

Jaana M. Hartikainen, M. Beckmann, P. Fasching, 2021, The New England journal of medicine.

BRCA2 mutation in a family with hereditary prostate cancer

H. Grönberg, Å. Borg, M. Emanuelsson, 2001, Genes, chromosomes & cancer.

Her-2/neu and INT2 proto-oncogene amplification in malignant breast tumors in relation to reproductive factors and exposure to exogenous hormones.

M. Fernö, J. Ranstam, Å. Borg, 1991, Journal of the National Cancer Institute.

Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170

Nicholas A. Sinnott-Armstrong, Richard C. Sallari, S. Cross, 2016, Nature Genetics.

Low frequency of E-cadherin alterations in familial breast cancer

A. Børresen-Dale, Å. Borg, N. Loman, 2001, Breast Cancer Research.

Variation of breast cancer risk among BRCA1/2 carriers.

C. Begg, J. Olsen, Å. Borg, 2008, JAMA.

Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer

Å. Borg, A. Lindblom, M. Nilbert, 2010, Familial Cancer.

BRCA1 1675delA and 1135insA Account for One Third of Norwegian Familial Breast-Ovarian Cancer and Are Associated with Later Disease Onset than Less Frequent Mutations

K. Heimdal, P. Møller, E. Hovig, 2002, Disease markers.

The CD44+/CD24- phenotype is enriched in basal-like breast tumors

M. Ringnér, L. Saal, M. Fernö, 2008, Breast Cancer Research.

Activated cell cycle checkpoints in epirubicin-treated breast cancer cells studied by BrdUrd-flow cytometry.

Å. Borg, S. Oredsson, B. Baldetorp, 1997, Cytometry.

Tiling resolution array CGH of dic(7;9)(p11∼13;p11∼13) in B-cell precursor acute lymphoblastic leukemia reveals clustered breakpoints at 7p11.2∼12.1 and 9p13.1

Å. Borg, M. Heidenblad, R. Hovland, 2007, Cytogenetic and Genome Research.

Estrogen receptor enzyme immunoassay in fine-needle aspirates from human breast cancer.

M. Fernö, Å. Borg, I. Idvall, 1989, Acta oncologica.

Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study.

M. King, D. Easton, M. Stratton, 1998, American journal of human genetics.

HER2/neu AMPLIFICATION AND COMEDO TYPE BREAST CARCINOMA

M. Fernö, Å. Borg, H. Sigurdsson, 1989, The Lancet.

Tiling resolution array CGH of dic(7;9)(p11 approximately 13;p11 approximately 13) in B-cell precursor acute lymphoblastic leukemia reveals clustered breakpoints at 7p11.2 approximately 12.1 and 9p13.1.

Å. Borg, M. Heidenblad, R. Hovland, 2007, Cytogenetic and genome research.

Chromosome I alterations in breast cancer: Allelic loss on Ip and Iq Is related to lymphogenic metastases and poor prognosis

Å. Borg, H. Olsson, Qiu‐xia Zhang, 1992 .

Substantial intrinsic variability in chemoradiosensitivity of newly established anaplastic thyroid cancer cell-lines

Å. Borg, E. Brun, K. Paulsson, 2020, Acta oto-laryngologica.

BRCA1 and BRCA2 mutations among breast cancer patients from the Philippines

Å. Borg, S. Narod, A. Liede, 2002, International journal of cancer.

Two BRCA1-positive epithelial ovarian tumors with metastases to the central nervous system: a case report.

Å. Borg, N. Loman, S. Malander, 2001, Gynecologic Oncology.

CASE REPORT Two BRCA1-Positive Epithelial Ovarian Tumors with Metastases to the Central Nervous System: A Case Report

Å. Borg, N. Loman, S. Malander, 2001 .

Biallelic germline nonsense variant of MLH3 underlies polyposis predisposition

Å. Borg, A. Ristimäki, P. Peltomäki, 2018, Genetics in Medicine.

Gene expression in inherited breast cancer.

M. Ringnér, J. Trent, Å. Borg, 2002, Advances in cancer research.

BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer

Å. Borg, N. Loman, T. Törngren, 2017, Breast Cancer Research and Treatment.

Chromosome 1 alterations in breast cancer: allelic loss on 1p and 1q is related to lymphogenic metastases and poor prognosis.

Å. Borg, H. Olsson, E. Wenngren, 1992, Genes, chromosomes & cancer.

Genetic profiles of gastroesophageal cancer: combined analysis using expression array and tiling array--comparative genomic hybridization.

Å. Borg, M. Ohlsson, J. Staaf, 2010, Cancer genetics and cytogenetics.

High‐resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization

Johan Staaf, Mattias Höglund, Markus Ringnér, 2007, Genes, chromosomes & cancer.

BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data

S. Gruvberger, L. Saal, C. Peterson, 2002, Genome Biology.

Comprehensive mutational analysis of a cohort of Swedish Cornelia de Lange syndrome patients

Å. Borg, A. Nordgren, J. Staaf, 2007, European Journal of Human Genetics.

The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions

H A Risch, J. Hopper, M. Southey, 2008, British Journal of Cancer.

MYB oncogene amplification in hereditary BRCA1 breast cancer.

J M Trent, J Isola, J. Trent, 2000, Cancer research.

Advances in Brief MYB Oncogene Amplification in Hereditary BRCA 1 Breast Cancer 1

J. Trent, D. Duggan, Å. Borg, 2000 .

Discussion on the use of taxanes for treatment of breast cancers in BRCA1 mutations carriers

P. Møller, Å. Borg, N. Loman, 2007, Hereditary cancer in clinical practice.

Prognostic potential of flow cytometric S-phase and ploidy prospectively determined in primary breast carcinomas

Å. Borg, E. Långström, B. Baldetorp, 1991, Breast Cancer Research and Treatment.

Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation.

M. Ringnér, P. Lønning, Å. Borg, 2015, The Journal of investigative dermatology.

Cancer-associated fibroblasts expressing CXCL14 rely upon NOS1-derived nitric oxide signaling for their tumor-supporting properties.

Å. Borg, Sabine U. Vorrink, O. Frings, 2014, Cancer research.

Spatial deconvolution of HER2-positive breast cancer delineates tumor-associated cell type interactions

Å. Borg, J. Lundeberg, A. Ehinger, 2021, Nature Communications.

A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients

E. Kalso, Å. Borg, H. Nevanlinna, 2021, Scientific Reports.

FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population

Sofia Khan, J. Schleutker, Å. Borg, 2017, Breast Cancer Research and Treatment.

Case-control analysis of truncating mutations in DNA damage response genes connects TEX15 and FANCD2 with hereditary breast cancer susceptibility

J. Schleutker, Å. Borg, H. Nevanlinna, 2017, Scientific Reports.

Breast tumors from CHEK2 1100delC-mutation carriers: genomic landscape and clinical implications

D. Greco, Å. Borg, H. Nevanlinna, 2011, Breast Cancer Research.

Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness.

Stefania Tommasi, Laura Cortesi, Mads Thomassen, 2019, Cancer research.

Reproductive factors and risk of contralateral breast cancer by BRCA1 and BRCA2 mutation status: results from the WECARE study

C. Begg, Å. Borg, L. Bernstein, 2010, Cancer Causes & Control.

Tumour biological features of BRCA1-induced breast and ovarian cancer.

Å. Borg, O. Johannsson, H. Olsson, 1997, European journal of cancer.

Estrogen and Progesterone Receptor Analyses in More Than 4000 Human Breast Cancer Samples: A Study with Special Reference to Age at diagnosis and stability of analyses

M. Fernö, Å. Borg, H. Olsson, 1990 .

Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

Jack A. Taylor, W. Chung, S. Cross, 2019, bioRxiv.

Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers

W. Chung, R. Nussbaum, F. Couch, 2017, Journal of the National Cancer Institute.

Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers

R. Nussbaum, D. Steinemann, V. Pankratz, 2014, Breast Cancer Research.

Indicators of prognosis in node-negative breast cancer.

M. Fernö, Å. Borg, H. Olsson, 1990, The New England journal of medicine.

MiRNA expression in urothelial carcinomas: Important roles of miR‐10a, miR‐222, miR‐125b, miR‐7 and miR‐452 for tumor stage and metastasis, and frequent homozygous losses of miR‐31

Å. Borg, M. Höglund, J. Staaf, 2009, International journal of cancer.

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.

Hanina Hibshoosh, Xiaomei Wang, Matthew Maurer, 2005, Cancer research.

Multidimensional transcriptomics provides detailed information about immune cell distribution and identity in HER2+ breast tumors

Joakim Lundeberg, Jari Häkkinen, Johan Vallon-Christersson, 2018, bioRxiv.

Mutual Exclusivity Analysis of Genetic and Epigenetic Drivers in Melanoma Identifies a Link Between p14ARF and RARβ Signaling

Å. Borg, G. Jönsson, P. Guldberg, 2013, Molecular Cancer Research.

Cell Cycle and Senescence Mutual Exclusivity Analysis of Genetic and Epigenetic Drivers in Melanoma Identi fi es a Link Between p 14 ARF and RAR b Signaling

Å. Borg, P. Guldberg, G. Pawelec, 2013 .

Genomic profiling of bone and soft tissue tumors with supernumerary ring chromosomes using tiling resolution bacterial artificial chromosome microarrays

Å. Borg, M. Höglund, G. Jönsson, 2006, Oncogene.

Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer.

P. Meltzer, Å. Borg, O. Johannsson, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors

Mattias Höglund, Srinivas Veerla, Åke Borg, 2008, BMC Medical Genomics.

Mapping of a novel ocular and cutaneous malignant melanoma susceptibility locus to chromosome 9q21.32.

Å. Borg, H. Olsson, C. Ingvar, 2005, Journal of the National Cancer Institute.

Characterisation of dic(9;20)(p11–13;q11) in childhood B‐cell precursor acute lymphoblastic leukaemia by tiling resolution array‐based comparative genomic hybridisation reveals clustered breakpoints at 9p13.2 and 20q11.2

Å. Borg, B. Johansson, A. Nordgren, 2006, British journal of haematology.

Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes

M. Ringnér, L. Saal, M. Fernö, 2012, Molecular oncology.

Transcriptome ‐ wide association study of breast cancer risk by estrogen ‐ receptor status

Jack A. Taylor, W. Chung, S. Cross, 2020 .

Precision Oncology of High-Grade Ovarian Cancer Defined through Targeted Sequencing

Å. Borg, J. Carlson, T. Petta, 2021, Cancers.

HRDetect : A mutational signature based predictor of BRCA 1 and BRCA 2 deficiency

Alastair, Steven, Anne, 2017 .

Cancer predisposing BARD1 mutations in breast–ovarian cancer families

Å. Borg, A. Piskorz, J. Limon, 2011, Breast Cancer Research and Treatment.

Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification

Katherine M. Tucker, Sebastian A. Wagner, Kelly J. Sullivan, 2019, Human Mutation.

High allele loss rates at I7q I2‐q2I in breast and ovarian tumors from BRCAI‐linked families

J. Chang-Claude, B. Ponder, C. Larsson, 1995 .

Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women

Olufunmilayo I. Olopade, Mads Thomassen, Dieter Niederacher, 2016, Breast Cancer Research.

Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers

W. B. Archey, K. Offit, Å. Borg, 2002, Oncogene.

High frequency of allelic imbalance at the BRCA1 region on chromosome 17q in both familial and sporadic ductal breast carcinomas.

Å. Borg, O. Johannsson, H. Olsson, 1994, Journal of the National Cancer Institute.

Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.

Johan Staaf, Mårten Fernö, Markus Ringnér, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BRCA2 mutations in 154 finnish male breast cancer patients.

Anssi Auvinen, A. Auvinen, K. Waltering, 2004, Neoplasia.

BRCA1 and BRCA2 mutation analysis in breast‐ovarian cancer families from northeastern Poland

Å. Borg, J. Limon, U. Johansson, 2003, Human mutation.

Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants

W. Chung, T. Fehm, T. Rebbeck, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of novel candidate genes associated with cleft lip and palate using array comparative genomic hybridisation

J C Murray, R Pfundt, R. Pfundt, 2007, Journal of Medical Genetics.

Somatic mutations reveal asymmetric cellular dynamics in the early human embryo

M. Hurles, A. Børresen-Dale, M. Stratton, 2017, Nature.

BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland.

Å. Borg, J. Jassem, G. Palmieri, 2008, Oncology reports.

Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer.

Å. Borg, N. Loman, O. Johannsson, 1997, American journal of human genetics.

Molecular and pathological characterization of inherited breast cancer.

Å. Borg, Å. Borg, 2001, Seminars in cancer biology.

Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells

Carlos Caldas, Fengtang Yang, Rosalind Eeles, 2015, Genome research.

AURKA F31I Polymorphism and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Consortium of Investigators of Modifiers of BRCA1/2 Study

R. Vierkant, T. Sellers, V. Pankratz, 2007, Cancer Epidemiology Biomarkers & Prevention.

AURKA F 31 I Polymorphism and Breast Cancer Risk in BRCA 1 and BRCA 2 Mutation Carriers : A Consortium of Investigators of Modifiers of BRCA 1 / 2 Study

R. Vierkant, T. Sellers, J. Olson, 2007 .

Genome-wide DNA Methylation Analysis of Lung Carcinoma Reveals One Neuroendocrine and Four Adenocarcinoma Epitypes Associated with Patient Outcome

Johan Staaf, Hans Brunnström, Mats Jönsson, 2014, Clinical Cancer Research.

High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.

Kerstin, Å. Borg, O. Johannsson, 2000, Journal of the National Cancer Institute.

Identification of new microRNAs in paired normal and tumor breast tissue suggests a dual role for the ERBB2/Her2 gene.

Å. Borg, N. Loman, J. Vallon-Christersson, 2011, Cancer research.

Genomic profiling of malignant melanoma using tiling-resolution arrayCGH

M. Ringnér, Å. Borg, G. Jönsson, 2007, Oncogene.

Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

Jane E. Carpenter, Jack A. Taylor, W. Chung, 2019, Nature Genetics.

High-definition spatial transcriptomics for in situ tissue profiling

Patrik L. Ståhl, Richard Bonneau, A. Regev, 2019, Nature Methods.

Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease

Mårten Fernö, Helena Jernström, Christian Ingvar, 2015, EMBO molecular medicine.

A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions.

S. Hilsenbeck, W. Friedrichs, P. O’Connell, 2000, Cancer research.

The HER2-Encoded miR-4728-3p Regulates ESR1 through a Non-Canonical Internal Seed Interaction

R. Søkilde, Å. Borg, J. Vallon-Christersson, 2014, PloS one.

Molecular and Cellular Pathobiology Identification of New MicroRNAs in Paired Normal and Tumor Breast Tissue Suggests a Dual Role for the ERBB 2 / Her 2 Gene

Å. Borg, N. Loman, J. Vallon-Christersson, 2010 .

The non-coding RNA of the multidrug resistance-linked vault particle encodes multiple regulatory small RNAs

Johan Vallon-Christersson, Carlos Rovira, Åke Borg, 2009, Nature Cell Biology.

BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.

Dong Liang, Patrick Neven, Harvey Risch, 2016, Journal of the National Cancer Institute.

Tumor Genome Wide DNA Alterations Assessed by Array CGH in Patients with Poor and Excellent Survival Following Operation for Colorectal Cancer

Å. Borg, G. Jönsson, J. Staaf, 2007, Cancer informatics.

Identification of TP53 gene mutations in uterine corpus cancer with short follow-up.

Å. Borg, T. Högberg, D. Killander, 1997, Gynecologic oncology.

Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML

K. Stegmaier, M. Hemann, Å. Borg, 2015, Oncogene.

BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk

F. Couch, J. Benítez, A. Spurdle, 2012, Journal of Medical Genetics.

BRCA 1 R 1699 Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk

F. Couch, A. Spurdle, Å. Borg, 2012 .

Expanding the genotype–phenotype spectrum in hereditary colorectal cancer by gene panel testing

Å. Borg, M. Nilbert, T. Törngren, 2016, Familial Cancer.

Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer

Gord Glendon, Lesley McGuffog, Daniel Barrowdale, 2012 .

Genetic epidemiology of BRCA1 mutations in Norway.

K. Heimdal, P. Møller, E. Hovig, 2001, European journal of cancer.

Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families.

P. Møller, Å. Borg, N. Loman, 2001, Human molecular genetics.

Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma

M. Ringnér, Å. Borg, H. Olsson, 2012, Clinical Cancer Research.

Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype.

Å. Borg, J. Vallon-Christersson, L. Poellinger, 2006, Cancer cell.

An integrated genomics analysis of epigenetic subtypes in human breast tumors links DNA methylation patterns to chromatin states in normal mammary cells

M. Ringnér, Å. Borg, M. Höglund, 2016, Breast Cancer Research.

Distinct Gene Expression Signatures in Lynch Syndrome and Familial Colorectal Cancer Type X

Å. Borg, Srinivas Veerla, I. Bernstein, 2013, BMC Proceedings.

Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study

A. Børresen-Dale, C. Begg, Å. Borg, 2010, Human mutation.

Classification of BRCA1 missense variants of unknown clinical significance

F. Barany, Å. Borg, G. Chenevix-Trench, 2005, Journal of Medical Genetics.

One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden.

Å. Borg, N. Loman, H. Olsson, 2004, European journal of cancer.

Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer

M. Daly, D. Altshuler, F. Couch, 2010, PLoS genetics.

Biallelic germline nonsense variant of MLH3 underlies polyposis predisposition

Å. Borg, A. Ristimäki, P. Peltomäki, 2018, Genetics in Medicine.

Clinical and histopathological features of malignant melanoma in germline CDKN2A mutation families

Å. Borg, H. Olsson, C. Ingvar, 2002, Melanoma research.

Prevalence of germline TP53 mutations and history of Li–Fraumeni syndrome in families with childhood adrenocortical tumors, choroid plexus tumors, and rhabdomyosarcoma: A population‐based survey

D. Gisselsson, Å. Borg, H. Olsson, 2012, Pediatric blood & cancer.

Molecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapy

Johan Staaf, Frida Rosengren, Markus Ringnér, 2015, Oncotarget.

CITED 1 is a novel binding partner of MITF that influences the MITF-directed 1 transcriptional profile in melanoma 2

Å. Borg, M. Lauss, G. Jönsson, 2017 .

Clinical Utility of Targeted Sequencing in Lung Cancer: Experience From an Autonomous Swedish Health Care Center

Å. Borg, G. Jönsson, J. Staaf, 2020, JTO clinical and research reports.

Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer.

K. Porkka, T. Visakorpi, Å. Borg, 1999, The American journal of pathology.

Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers

W. Chung, D. Steinemann, F. Couch, 2019, British Journal of Cancer.

Detection of submicroscopic constitutional chromosome aberrations in clinical diagnostics: a validation of the practical performance of different array platforms

Johan Staaf, Åke Borg, Sok Kean Khoo, 2008, European Journal of Human Genetics.

Gene‐panel testing of breast and ovarian cancer patients identifies a recurrent RAD51C duplication

F. Couch, Å. Borg, H. Nevanlinna, 2018, Clinical genetics.

Loss of heterozygosity at BRCA2 in a ductal carcinoma in situ and three invasive breast carcinomas in a family with a germline BRCA2 mutation

Å. Borg, K. Olsen, A. Gerdes, 2004, Breast Cancer Research and Treatment.

Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer

Å. Borg, L. Ek, K. Jirström, 2017, Oncotarget.

Molecular and Cellular Pathobiology The Retinoblastoma Gene Undergoes Rearrangements in BRCA 1-De fi cient Basal-like Breast Cancer

M. Ringnér, L. Saal, M. Fernö, 2012 .

The spatial RNA integrity number assay for in situ evaluation of transcriptome quality

Å. Borg, L. Fugger, J. Lundeberg, 2021, Communications biology.

Human breast cancer in situ capturing transcriptomics

Å. Borg, J. Lundeberg, L. Bergenstråhle, 2020 .

P. Oefner, T. Helbich, Å. Borg, 1998, International journal of cancer.

Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

Jane E. Carpenter, Jack A. Taylor, W. Chung, 2019, Nature Communications.

Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer

Johan Staaf, Markus Ringnér, Åke Borg, 2011, Breast Cancer Research.

Normalization of Illumina Infinium whole-genome SNP data improves copy number estimates and allelic intensity ratios

Johan Staaf, David Lindgren, Mattias Höglund, 2008, BMC Bioinformatics.

Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors

Å. Borg, B. Agnarsson, R. Barkardottir, 2006, International journal of cancer.

High expression of ZNF703 independent of amplification indicates worse prognosis in patients with luminal B breast cancer

M. Ringnér, Å. Borg, O. Johannsson, 2013, Cancer medicine.

HER-2/neu amplification predicts poor survival in node-positive breast cancer.

W. McGuire, M. Fernö, S. Fuqua, 1990, Cancer research.

Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study.

Katherine M. Tucker, W. Chung, R. Nussbaum, 2018, Journal of the National Cancer Institute.

Impact of a paternal origin of germline BRCA1/2 mutations on the age at breast and ovarian cancer diagnosis in a Southern Swedish cohort

Å. Borg, H. Olsson, P. Broberg, 2015, Genes, chromosomes & cancer.

Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: enrichment in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other malignancies

J. Kere, L. Aaltonen, P. Møller, 2006, Journal of Medical Genetics.

Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.

Å. Borg, N. Loman, O. Johannsson, 2001, Journal of the National Cancer Institute.

First BRCA1 and BRCA2 gene testing implemented in the health care system of Stockholm.

Å. Borg, A. Lindblom, B. Arver, 2001, Genetic testing.

Prognosis and clinical presentation of BRCA2-associated breast cancer.

Å. Borg, N. Loman, O. Johannsson, 2000, European journal of cancer.

Cytogenetic heterogeneity and clonal evolution in synchronous bilateral breast carcinomas and their lymph node metastases from a male patient without any detectable BRCA2 germline mutation.

Å. Borg, F. Mertens, B. Baldetorp, 2000, Cancer genetics and cytogenetics.

BRCA1-positive patients are small for gestational age compared with their unaffected relatives.

Å. Borg, O. Johannsson, H. Olsson, 1998, European journal of cancer.

Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns

Johan Staaf, Markus Ringnér, Johan Vallon-Christersson, 2010, Breast Cancer Research.

Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations.

J Isola, Å. Borg, O. Kallioniemi, 1997, Cancer research.

Prognostic significance of estrogen and progesterone receptors in stage ii breast cancer

M. Fernö, Å. Borg, T. Möller, 1988, Journal of surgical oncology.

Recruitment of HIF-1 a and HIF-2 a to common target genes is differentially regulated in neuroblastoma : HIF-2 a promotes an aggressive phenotype

Å. Borg, J. Vallon-Christersson, L. Poellinger, 2022 .

Endothelial Induced EMT in Breast Epithelial Cells with Stem Cell Properties

Markus Ringnér, Magnus K. Magnusson, Thorarinn Gudjonsson, 2011, PloS one.

Involvement of adenomatous polyposis coli (APC)/β-catenin signalling in human breast cancer

Å. Borg, T. Andersson, M. Nilbert, 2000 .

Absence of the common IGF1 19 CA-repeat allele is more common among BRCA1 mutation carriers than among non-carriers from BRCA1 families

Å. Borg, H. Jernström, M. Henningson, 2007, Familial Cancer.

Insulin-like growth factor-1 (IGF1) genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating IGF-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families

Å. Borg, H. Jernström, H. Olsson, 2005, British Journal of Cancer.

Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families.

Julie O. Culver, F. Couch, E. Goode, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers

M. Ringnér, L. Saal, M. Fernö, 2011, BMC Cancer.

Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization.

Jorma Isola, Bo Baldetorp, Å. Borg, 2003, Cancer research.

Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q

Å. Borg, M. Höglund, T. Fioretos, 2006, Oncogene.

Detecting EGFR alterations in clinical specimens—pitfalls and necessities

Å. Borg, L. Johansson, K. Jirström, 2013, Virchows Archiv.

TP53 protein expression analysis by luminometric immunoassay in comparison with gene mutation status and prognostic factors in early stage endometrial cancer

M. Fernö, Å. Borg, R. Willén, 2002, International Journal of Gynecologic Cancer.

Molecular and Cellular Pathobiology The Retinoblastoma Gene Undergoes Rearrangements in BRCA 1-De fi cient Basal-like Breast Cancer

L. Saal, Å. Borg, N. Loman, 2012 .

BIOINFORMATICS ORIGINAL PAPER doi:10.1093/bioinformatics/btm359 Data and text mining

Johan Staaf, Jian Huang, Åke Borg, 2022 .

Recurrent and multiple bladder tumors show conserved expression profiles

Å. Borg, M. Höglund, T. Fioretos, 2008, BMC Cancer.

Association of INT2/HST1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis.

M. Fernö, Å. Borg, H. Olsson, 1991, British Journal of Cancer.

Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis

Mef Nilbert, Å. Borg, P. Bendahl, 2002, Cancer.

Flow cytometric DNA index and S-phase fraction in breast cancer in relation to other prognostic variables and to clinical outcome.

M. Fernö, Å. Borg, H. Olsson, 1992, Acta oncologica.

ERBB2 amplification in breast cancer with a high rate of proliferation.

M. Fernö, Å. Borg, H. Olsson, 1991, Oncogene.

Genetic aberrations in hypodiploid breast cancer: frequent loss of chromosome 4 and amplification of cyclin D1 oncogene.

M. Fernö, Å. Borg, J. Isola, 1998, The American journal of pathology.

Polygenic risk modeling for prediction of epithelial ovarian cancer risk

A. Whittemore, W. Chung, L. Kiemeney, 2022, European Journal of Human Genetics.

Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores

F. Couch, O. Olopade, J. Benítez, 2021, Journal of the National Cancer Institute.

Frequent Amplification of Chromosomal Region 20 q 12-q 13 in Ovarian Cancer 1

Åke Borg, P. Meltzer, Å. Borg, 2000 .

A genomic map of a 6-Mb region at 13q21-q22 implicated in cancer development: identification and characterization of candidate genes

Heli Nevanlinna, Therese Sandberg, Dietrich A. Stephan, 2002, Human Genetics.

Characterisation of amplification patterns and target genes at chromosome 11q13 in CCND1-amplified sporadic and familial breast tumours

M. Ringnér, Å. Borg, R. Barkardottir, 2012, Breast Cancer Research and Treatment.

Pregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers

Å. Borg, N. Loman, H. Olsson, 1998, The Lancet.

Lack of HIN-1 methylation in BRCA1-linked and "BRCA1-like" breast tumors.

A. Richardson, Å. Borg, K. Polyak, 2003, Cancer research.

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

Jane E. Carpenter, Jack A. Taylor, W. Chung, 2021, Nature Communications.

Molecular analyses of triple-negative breast cancer in the young and elderly

J. Hartman, Å. Borg, A. Ehinger, 2021, Breast cancer research : BCR.

Analysis of fusion transcripts indicates widespread deregulation of snoRNAs and their host genes in breast cancer

R. Søkilde, Å. Borg, M. Höglund, 2020, International journal of cancer.

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

Lara E Sucheston-Campbell, Simon G. Coetzee, Dennis J. Hazelett, 2017, Nature Genetics.

Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors

Å. Borg, N. Loman, J. Isola, 2005, Modern Pathology.

Reduced testosterone, 17β-oestradiol and sexual hormone binding globulin, and increased insulin-like growth factor-1 concentrations, in healthy nulligravid women aged 19-25 years who were first and/or second degree relatives to breast cancer patients

Å. Borg, H. Jernström, H. Olsson, 1997, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. The BRCA1 Exon 13 Duplication Screening Group.

M. Beckmann, T. Sellers, M. Stratton, 2000, American journal of human genetics.

Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas

Å. Borg, M. Dictor, K. Miura, 2000, British Journal of Cancer.

Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic

L. Saal, Å. Borg, N. Loman, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant

W. Chung, F. Couch, O. Olopade, 2021, Genetics in Medicine.

Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer

Å. Borg, K. Holm, B. Nordenskjöld, 2008, Breast Cancer Research.

Improving surveillance and quality of life of BRCA mutation carriers.

Å. Borg, N. Loman, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Detection and delineation of an unusual 17p11.2 deletion by array-CGH and refinement of the Smith-Magenis syndrome minimum deletion to similar to 650 kb

Å. Borg, G. Jönsson, J. Staaf, 2005 .

Isochromosome 17q in blast crisis of chronic myeloid leukemia and in other hematologic malignancies is the result of clustered breakpoints in 17p11 and is not associated with coding TP53 mutations.

Å. Borg, M. Höglund, B. Johansson, 1999, Blood.

Isochromosome 17 q in Blast Crisis of Chronic Myeloid Leukemia and in Other Hematologic Malignancies Is the Result of Clustered Breakpoints in 17 p 11 and Is Not Associated With Coding TP 53 Mutations

Å. Borg, M. Höglund, B. Johansson, 1999 .

The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions

J. Hopper, D. Easton, P. Pharoah, 2008, British Journal of Cancer.

Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer

Joshua M. Korn, Debra, M. Daly, 2010, PLoS genetics.

Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers.

F. Couch, B. Karlan, J. Benítez, 2011, Journal of the National Cancer Institute.

Prognostic significance of flow cytometric DNA analysis and estrogen receptor content in breast carcinomas — a 10 year survival study

M. Fernö, Å. Borg, E. Långström, 2005, Breast Cancer Research and Treatment.

Variation of Breast Cancer Risk Among BRCA 1 / 2 Carriers : An Investigation by the WECARE Study Group

C. Begg, J. Olsen, Å. Borg, 2009 .

CHEK2 1100delC in patients with metachronous cancers of the breast and the colorectum

Å. Borg, M. Nilbert, Anna Isinger, 2006, BMC Cancer.

Characterization of topoisomerase IIα gene amplification and deletion in breast cancer

Jorma Isola, Åke Borg, Å. Borg, 1999 .

Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay.

M. Fernö, Å. Borg, H. Olsson, 1996, European journal of cancer.

Cathepsin D, both a prognostic factor and a predictive factor for the effect of adjuvant tamoxifen in breast cancer. South Sweden Breast Cancer Group.

M. Fernö, Å. Borg, H. Olsson, 1994, European journal of cancer.

Predicting continuous values of prognostic markers in breast cancer from microarray gene expression profiles.

Carsten Peterson, Patrik Edén, Mårten Fernö, 2004, Molecular cancer therapeutics.

BRCA1/BRCA2 founder mutations and cancer risks: impact in the western Danish population

Å. Borg, M. Thomassen, S. Ladelund, 2016, Familial Cancer.

The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium

A. Spurdle, Å. Borg, P. Devilee, 2017, Journal of Medical Genetics.

Alternative splicing and ACMG-AMP-2015-based classification of PALB2 genetic variants: an ENIGMA report

Sitao Wu, A. Spurdle, M. Southey, 2019, Journal of Medical Genetics.

Genetic profiles distinguish different types of hereditary ovarian cancer.

Å. Borg, G. Jönsson, J. Staaf, 2010, Oncology reports.

Breast cancer risk variants at 6 q 25 display different phenotype associations and regulate ESR 1 , RMND 1 and CCDC 170

Wei Zheng, Mads Thomassen, Nicholas A. Sinnott-Armstrong, 2016 .

Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers.

F. Couch, T. Rebbeck, J. Benítez, 2011, Human molecular genetics.

Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort

Jingmei Li, K. Czene, P. Hall, 2018, International Journal of Cancer.

Written pretest information and germline BRCA1/2 pathogenic variant testing in unselected breast cancer patients: predictors of testing uptake

Å. Borg, N. Loman, M. Nilsson, 2018, Genetics in Medicine.

Hemizygosity for chromosome 2q14.2‐q22.1 spanning the GLI2 and PROC genes associated with growth hormone deficiency, polydactyly, deep vein thrombosis and urogenital abnormalities

Å. Borg, G. Jönsson, J. Staaf, 2006, Clinical genetics.

BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer

Å. Borg, T. Hansen, F. Nielsen, 2008, Acta oncologica.

Detection and precise mapping of germline rearrangements in BRCA1, BRCA2, MSH2, and MLH1 using zoom‐in array comparative genomic hybridization (aCGH)

Å. Borg, J. Staaf, M. Nilbert, 2008, Human mutation.

Clinical Value of RNA Sequencing–Based Classifiers for Prediction of the Five Conventional Breast Cancer Biomarkers: A Report From the Population-Based Multicenter Sweden Cancerome Analysis Network—Breast Initiative

Christian Brueffer, Martin Malmberg, Jari Häkkinen, 2018, JCO precision oncology.

Chromosome aberrations in prophylactic mastectomies from women belonging to breast cancer families.

Å. Borg, H. Olsson, F. Mitelman, 1996, Genes, chromosomes & cancer.

The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer.

Å. Borg, M. Nilbert, B. Halvarsson, 2006, Gynecologic oncology.

Non-coding antisense transcription detected by conventional and single-stranded cDNA microarray

Å. Borg, J. Vallon-Christersson, J. Staaf, 2007, BMC Genomics.

TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc‐binding domains

E. Hovig, Å. Borg, J. Eyfjörd, 1995, Genes, chromosomes & cancer.

Male Breast Carcinoma after Irradiation and Long-Term Phenothiazine Exposure: A Case Report

Toshima Z. Parris, Å. Borg, K. Helou, 2020, Case Reports in Oncology.

Integrating spatial gene expression and breast tumour morphology via deep learning

James Y. Zou, J. Maaskola, Å. Borg, 2020, Nature Biomedical Engineering.

Amplification and overexpression of the ABCC3 (MRP3) gene in primary breast cancer

Å. Borg, J. Isola, J. Staaf, 2012, Genes, chromosomes & cancer.

Enzyme immunoassay of progesterone receptor in breast cancer biopsy samples. A comparison with the dextran coated charcoal method.

M. Fernö, Å. Borg, U. Johansson, 1989, Acta oncologica.

Screening for copy‐number alterations and loss of heterozygosity in chronic lymphocytic leukemia—A comparative study of four differently designed, high resolution microarray platforms

Hanna Göransson, Anders Isaksson, Johan Staaf, 2008, Genes, chromosomes & cancer.

High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer

M. Ringnér, Å. Borg, I. Hedenfalk, 2011, Breast Cancer Research and Treatment.

Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer.

Å. Borg, J. Isola, M. Bärlund, 1999, Genes, chromosomes & cancer.

CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk

Å. Borg, H. Olsson, O. Bratt, 1999, British Journal of Cancer.

Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer

Å. Borg, K. Jirström, G. Jönsson, 2015, Oncotarget.

ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer.

M. Fernö, Å. Borg, H. Olsson, 1994, Cancer letters.

Cytogenetic characterization and gene expression profiling of the trastuzumab-resistant breast cancer cell line JIMT-1.

Å. Borg, J. Isola, G. Jönsson, 2007, Cancer genetics and cytogenetics.

Enzyme immuno assay of the estrogen receptor in breast cancer biopsy samples. A comparison with isoelectric focusing.

M. Fernö, Å. Borg, G. Sellberg, 1986, Acta radiologica. Oncology.

Improved method for assay of estradiol and progesterone receptors with special reference to breast cancer.

M. Fernö, Å. Borg, U. Johansson, 1982, Anticancer research.

High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families

Å. Borg, H. Olsson, C. Ingvar, 2014, Journal of Medical Genetics.

Confirmed cancer trends in families of patients with multiple cancers including cutaneous melanoma

K. Nielsen, Å. Borg, H. Olsson, 2007, The British journal of dermatology.

Hormone-independent Activity from a Metastatic Breast Cancer An Estrogen Receptor Mutant with Strong Updated Version

Å. Borg, D. Wolf, Qiu‐xia Zhang, 2006 .

Advances in Brief An Estrogen Receptor Mutant with Strong Hormone-independent Activity from a Metastatic Breast Cancer '

Suzanne, Douglas, Å. Borg, 2006 .

An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer.

S. Fuqua, Å. Borg, S. Oesterreich, 1997, Cancer research.

Deletions on chromosome 4 in sporadic and BRCA mutated tumors and association with pathological variables.

Å. Borg, H. Olsson, B. Agnarsson, 2004, Anticancer research.

Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers.

Å. Borg, N. Loman, O. Johannsson, 1999, European journal of cancer.

Observations on wet weight, protein and DNA as reference for steroid receptors in malignant mammary tumours.

M. Fernö, Å. Borg, A. Norgren, 1986, Anticancer research.

Flow cytometry in primary breast cancer: improving the prognostic value of the fraction of cells in the S-phase by optimal categorisation of cut-off levels.

M. Fernö, J. Ranstam, Å. Borg, 1990, British Journal of Cancer.

Genome-wide search for breast cancer linkage in large Icelandic non-BRCA1/2 families

E. Gillanders, P. Møller, Å. Borg, 2010, Breast Cancer Research.

The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases

B. Bonanni, M. Urioste, J. Benítez, 2020, Cancers.

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

W. Chung, M. Beckmann, P. Fasching, 2019, npj Breast Cancer.

Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy

A. Howell, K. Heimdal, P. Møller, 2002, International journal of cancer.

Identification of cryptic aberrations and characterization of translocation breakpoints using array CGH in high hyperdiploid childhood acute lymphoblastic leukemia

Å. Borg, B. Johansson, T. Fioretos, 2006, Leukemia.

A comparison of two steroid receptor assays in breast cancer: dextran coated charcoal and isoelectric focusing.

M. Fernö, Å. Borg, A. Norgren, 1983, Anticancer research.

Expression profiling to predict outcome in breast cancer: the influence of sample selection

Carsten Peterson, Patrik Edén, Mårten Fernö, 2002, Breast Cancer Research.

[CDKN2A-mutation in a family with hereditary malignant melanoma].

Å. Borg, H. Lorentzen, A. Gerdes, 2014, Ugeskrift for laeger.

Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status

Å. Borg, N. Loman, H. Olsson, 2003, Breast Cancer Research.

High patient satisfaction with a simplified BRCA1/2 testing procedure: long-term results of a prospective study

Å. Borg, N. Loman, Y. Brandberg, 2018, Breast Cancer Research and Treatment.

High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer

Å. Borg, N. Loman, H. Olsson, 2014, Breast Cancer Research and Treatment.

Detection and delineation of an unusual 17p11.2 deletion by array-CGH and refinement of the Smith-Magenis syndrome minimum deletion to approximately 650 kb.

Å. Borg, G. Jönsson, J. Staaf, 2005, European journal of medical genetics.

ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer.

M. Fernö, P. Malmström, Å. Borg, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Histological specificity of alterations and expression of KIT and KITLG in non‐small cell lung carcinoma

Å. Borg, K. Jirström, J. Staaf, 2013, Genes, chromosomes & cancer.

Early oral contraceptive use as a prognostic factor in breast cancer.

M. Fernö, J. Ranstam, Å. Borg, 1988, Anticancer research.

Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations

B Johansson, M Fontes, Å. Borg, 2005, Leukemia.

Five novel somatic CDKN2/p16 mutations identified in melanoma, glioma and carcinoma of the pancreas. Mutations in brief no. 170. Online.

Å. Borg, G. Olafsdóttir, S. Gretarsdottir, 1998, Human mutation.

The Wilms' tumor gene 1 (WT1) induces expression of the N-myc downstream regulated gene 2 (NDRG2).

Å. Borg, J. Vallon-Christersson, U. Gullberg, 2007, DNA and cell biology.

Corrigendum: Signatures of mutational processes in human cancer

Roland Eils, Natalie Jäger, Adam P. Butler, 2013, Nature.

Expression and partial characterization of estramustine-binding protein (EMBP) in human breast cancer and malignant melanoma.

M. Fernö, Å. Borg, P. Björk, 1991, Anticancer research.

Serum selenium, selenoprotein P and glutathione peroxidase 3 as predictors of mortality and recurrence following breast cancer diagnosis: A multicentre cohort study

L. Saal, Å. Borg, J. Vallon-Christersson, 2021, Redox biology.

Duplication 16q12.1-q22.1 characterized by array CGH in a girl with spina bifida.

Å. Borg, J. Staaf, G. Annéren, 2007, European Journal of Medical Genetics.

Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

W. Chung, R. Nussbaum, D. Steinemann, 2014, Cancer Epidemiology, Biomarkers & Prevention.

Whole-genome-sequencing of triple negative breast cancers in a population-based clinical study

L. Saal, S. Nik-Zainal, H. Davies, 2019, Nature Medicine.

Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer

C. Begg, Å. Borg, L. Bernstein, 2010, Breast Cancer Research and Treatment.

European multicenter study on LOH of APOC3 at 11q23 in 766 breast cancer patients: relation to clinical variables

M. Beckmann, A. Børresen-Dale, D. Birnbaum, 1999, British Journal of Cancer.

Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies

D. Easton, J. Hopper, D. Easton, 2005, Journal of Medical Genetics.

Genetic Profiling Differentiates Second Primary Tumors from Metastases in Adult Metachronous Soft Tissue Sarcoma

Å. Borg, A. Carneiro, A. Rydholm, 2009, Sarcoma.

The FHIT and PTPRG genes are deleted in benign proliferative breast disease associated with familial breast cancer and cytogenetic rearrangements of chromosome band 3p14.

Å. Borg, F. Mitelman, F. Mertens, 1996, Cancer research.

Permanent alterations induced in plasma prolactin and estrogen receptor concentration in benign and malignant tissue of women who started oral contraceptive use at an early age.

M. Fernö, J. Ranstam, Å. Borg, 1987, Anticancer research.

Passenger strand loading in overexpression experiments using microRNA mimics

R. Søkilde, Å. Borg, H. Persson, 2015, RNA biology.

Infrequent occurrence of microsatellite instability in sporadic and familial breast cancer.

Å. Borg, O. Johannsson, O. Johannsson, 1995, European journal of cancer.

Antiestrogen binding sites in human breast cancer biopsies. Measurement ligand-specificity and affinity, and correlation to estrogen and progesterone receptors.

M. Fernö, Å. Borg, 1985, Anticancer research.

Advances in Brief A Hypersensitive Estrogen Receptor-a Mutation in Premalignant Breast Lesions 1

S. Hilsenbeck, W. Friedrichs, P. O’Connell, 2000 .

Interval breast cancer is associated with interferon immune response.

Jingmei Li, K. Czene, P. Hall, 2022, European journal of cancer.

Intratumor versus intertumor heterogeneity in gene expression profiles of soft‐tissue sarcomas

Patrik Edén, Thomas Breslin, Mef Nilbert, 2005, Genes, chromosomes & cancer.

Genetic predisposition to breast cancer.

Å. Borg, H. Olsson, 1996, Acta oncologica.

Association between breast cancer risk and disease aggressiveness: Characterizing underlying gene expression patterns

Jingmei Li, K. Czene, P. Hall, 2020, International journal of cancer.

Metachronous and Synchronous Occurrence of 5 Primary Malignancies in a Female Patient between 1997 and 2013: A Case Report with Germline and Somatic Genetic Analysis

Fredrik Persson, Åke Borg, Per Karlsson, 2017, Case Reports in Oncology.

EMQN Best Practice Guidelines for Molecular Genetic Analysis in Hereditary Breast/Ovarian Cancer

Å. Borg, N. Loman, C. Lázaro, 2008 .

Preexisting Somatic Mutations of Estrogen Receptor Alpha (ESR1) in Early-Stage Primary Breast Cancer

L. Saal, Å. Borg, N. Loman, 2021, JNCI cancer spectrum.

Combined analysis of P53 Arg72Pro, GSTM1 and GSTT1 gene polymorphisms as predisposing factors for non-small cell lung cancer (NSCLC) development

Å. Borg, R. Dziadziuszko, J. Jassem, 2005 .

Estrogen and progesterone receptors in melanoma metastases with special reference to analytical methods and prognosis.

M. Fernö, Å. Borg, C. Ingvar, 1984, Anticancer research.

Relationship of progesterone-receptor positivity in malignant breast tumors to reproductive status of women at tumor initiation--results from patients with possible radiation-induced tumors.

M. Fernö, Å. Borg, H. Olsson, 1990, Journal of the National Cancer Institute.

Accuracy of self-reported family history of cancer, mutation status and tumor characteristics in patients with early onset breast cancer

Å. Borg, H. Olsson, Carolina Ellberg, 2017, Acta oncologica.

Frequent miRNA-convergent fusion gene events in breast cancer

R. Søkilde, Å. Borg, M. Höglund, 2017, Nature Communications.

Refinement of breast cancer molecular classification by miRNA expression profiles

L. Saal, M. Fernö, R. Søkilde, 2019, BMC Genomics.

Predicting the future of breast cancer

Carsten Peterson, Mårten Fernö, Åke Borg, 2003, Nature Medicine.

Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer

L. Saal, M. Fernö, Å. Borg, 2019, Breast Cancer Research and Treatment.

Estrogen and progesterone receptor analyses in more than 4,000 human breast cancer samples. A study with special reference to age at diagnosis and stability of analyses. Southern Swedish Breast Cancer Study Group.

M. Fernö, Å. Borg, H. Olsson, 1990, Acta oncologica.

Genome-wide RNAi Screen Identifies Cohesin Genes as Modifiers of Renewal and Differentiation in Human HSCs.

B. Nilsson, Å. Borg, S. Soneji, 2016, Cell reports.

Prognostic implications of the expression levels of different immunoglobulin heavy chain-encoding RNAs in early breast cancer

L. Saal, Å. Borg, N. Loman, 2020, npj Breast Cancer.

Browsing data with Experiment Explorer

Carsten Peterson, Carl Troein, Johan Vallon-Christersson, 2011 .

IDENTIFICATION OF NOVEL SECRETED TUMOR STROMA-DERIVED STIMULATORS OF PROSTATE CANCER GROWTH

Å. Borg, F. Bruzzese, L. Egevad, 2009 .

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer

H. Ditzel, Å. Borg, I. Hedenfalk, 2021, Breast cancer research : BCR.

Germline mutations in BRCA1 and BRCA2 incidentally revealed in a biobank research study: experiences from re-contacting mutation carriers and relatives

L. Saal, Å. Borg, N. Loman, 2017, Journal of Community Genetics.

Proteomic analysis of breast tumors confirms the mRNA intrinsic molecular subtypes using different classifiers: a large-scale analysis of fresh frozen tissue samples

Å. Borg, Morten Krogh, T. Berggård, 2016, Breast Cancer Research.

Sample Preparation Approach Influences PAM50 Risk of Recurrence Score in Early Breast Cancer

Tonje G. Lien, T. Sørlie, Å. Borg, 2021, Cancers.

Functional characterization of novel germline TP53 variants in Swedish families

C. Larsson, Å. Borg, K. Wiman, 2019, Clinical genetics.

Tumor Genome Wide DNA Alterations Assessed by Array CGH in Patients with Poor and Excellent Survival following Operation for Colorectal Cancer

Å. Borg, G. Jönsson, J. Staaf, 2007, Cancer Informatics.

Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols.

M. Fernö, Å. Borg, D. Lane, 1995 .

Cytohesin 1 regulates homing and engraftment of human hematopoietic stem and progenitor cells.

Å. Borg, D. Bonnet, A. Kvist, 2017, Blood.

Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors

Å. Borg, M. Höglund, D. Lindgren, 2008 .

The topography of mutational processes in breast cancer genomes

E. Birney, A. Børresen-Dale, M. J. van de Vijver, 2016, Nature Communications.

Original Paper Infrequent Occurrence of Microsatellite Instability in Sporadic and Familial Breast Cancer

Å. Borg, M. Jiinsson, 1995 .

Estrogen Receptor β Expression Is Associated with Tamoxifen Response in ERα-Negative Breast Carcinoma

L. Saal, M. Fernö, C. Peterson, 2007, Clinical Cancer Research.

Whole-genome-sequencing of triple negative breast cancers in a population-based clinical study

L. Saal, S. Nik-Zainal, H. Davies, 2019, Nature Medicine.

[Analysis of prognostic value of TP53 gene mutations in non-small cell lung cancer].

Å. Borg, R. Dziadziuszko, J. Jassem, 2005, Pneumonologia i alergologia polska.

Somatic mutations reveal asymmetric cellular dynamics in the early human embryo

M. Hurles, A. Børresen-Dale, M. Stratton, 2017, Nature.

Zoom-in array comparative genomic hybridization (aCGH) to detect germline rearrangements in cancer susceptibility genes.

Å. Borg, J. Staaf, 2010, Methods in molecular biology.

Two new studies suggest that tests based on Cyclin E or microarray analysis have the potential to outperform conventional criteria predicting the outcome of breast cancer.

M. Fernö, C. Peterson, Å. Borg, 2003 .

Germline mutations in BRCA1 and BRCA2 incidentally revealed in a biobank research study: experiences from re-contacting mutation carriers and relatives

L. Saal, Å. Borg, N. Loman, 2017, Journal of Community Genetics.

Corrigendum: Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells.

Carlos Caldas, Fengtang Yang, Rosalind Eeles, 2016, Genome research.

Promoter usage of BRCA1-IRIS

Å. Borg, C. Rovira, P. Medstrand, 2005, Nature Cell Biology.

Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences

E. Birney, M. Ringnér, A. Børresen-Dale, 2019, Nature.

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

Jane E. Carpenter, W. Chung, M. Beckmann, 2019, npj Breast Cancer.

BRCA1 mutations and survival in women with ovarian cancer.

J. Ranstam, Å. Borg, O. Johannsson, 1997, The New England journal of medicine.

Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.

V. Pankratz, F. Couch, O. Olopade, 2010, Cancer research.

Expanding the genotype–phenotype spectrum in hereditary colorectal cancer by gene panel testing

Å. Borg, M. Nilbert, A. Kvist, 2016, Familial Cancer.

Prognostic implications of the expression levels of different immunoglobulin heavy chain-encoding RNAs in early breast cancer

L. Saal, Å. Borg, N. Loman, 2020, npj Breast Cancer.

Abstract P1-18-10: Preoperative treatment of HER2-positive breast cancer in South Sweden. A retrospective, comprehensive survey of neo-adjuvant treated HER2-positve breast cancer in the SCAN-B project 2010-2017

L. Saal, Å. Borg, N. Loman, 2020 .

Gene Expression Profiling–Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome

M. Ringnér, P. Lønning, Å. Borg, 2010, Clinical Cancer Research.

Genome-wide RNAi Screen Identifies Cohesin Genes as Modifiers of Renewal and Differentiation in Human HSCs.

B. Nilsson, Å. Borg, S. Soneji, 2016, Cell reports.

Multiregion Whole-Exome Sequencing Uncovers the Genetic Evolution and Mutational Heterogeneity of Early-Stage Metastatic Melanoma.

Å. Borg, H. Olsson, M. Lauss, 2016, Cancer research.

Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort

Jingmei Li, K. Czene, H. Grönberg, 2018, International journal of cancer.

Normalization of Illumina Infinium whole-genome SNP data improves copy number estimates and allelic intensity ratios

M. Ringnér, Å. Borg, M. Höglund, 2008, BMC Bioinformatics.

Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study

A. Børresen-Dale, C. Begg, Å. Borg, 2010, Human mutation.

Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells

Fengtang Yang, A. Børresen-Dale, M. Stratton, 2015, Genome research.

Low frequency of E-cadherin alterations in familial breast cancer

A. Børresen-Dale, Å. Borg, N. Loman, 2001, Breast Cancer Research.

Cancer-associated fibroblasts expressing CXCL14 rely upon NOS1-derived nitric oxide signaling for their tumor-supporting properties.

Å. Borg, Sabine U. Vorrink, A. Östman, 2014, Cancer research.

Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences

E. Birney, M. Ringnér, A. Børresen-Dale, 2019, Nature.

Correlation between estradiol-17 beta and progesterone cytosol receptor concentration, histologic differentiation and 3H-thymidine incorporation in endometrial carcinoma.

M. Fernö, Å. Borg, C. Tropé, 1982, Anticancer research.

Integrating spatial gene expression and breast tumour morphology via deep learning

Ludvig Bergenstråhle, Joakim Lundeberg, Abubakar Abid, 2020, Nature Biomedical Engineering.

Variation of breast cancer risk among BRCA1/2 carriers.

C. Begg, J. Olsen, Å. Borg, 2008, JAMA.